Sometimes, health problems get so big that all parties involved in the diagnosis and treatment business need to put aside personal ambition, academic glory and immediate company profits, and work together to find a solution. Somehow this has happened in a big way for Alzheimer's research.
The NIH, the FDA, academic researchers and various medical imaging and drug development companies have been collaborating for the past 5 years on identifying biological markers for the progression of Alzheimer's Disease. By sharing, not just development funds, but also the data that comes out of the research, everyone is benefiting, not the least being the tens of millions who may be treated for Alzheimer's in the near future.
The driving force behind this effort is the Foundation for the National Institutes for Health. By sharing the energy, ideas, risks and benefits associated with this research, the partnership is able to confront challenges on a scale and complexity not otherwise possible. To wit: